Esperion Th (ESPR)

NASDAQ
11.58
-0.52(-4.30%)
After Hours
11.60
+0.02(+0.17%)
- Real-time Data
  • Volume:
    524,954
  • Bid/Ask:
    11.60/12.55
  • Day's Range:
    11.56 - 12.27

ESPR Overview

Prev. Close
12.1
Day's Range
11.56-12.27
Revenue
62.11M
Open
12.03
52 wk Range
10.98-39.49
EPS
-12.12
Volume
524,954
Market Cap
327.45M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
719,068
P/E Ratio
-
Beta
1.13
1-Year Change
-67.88%
Shares Outstanding
28,277,493
Next Earnings Date
Nov 09, 2021
What is your sentiment on Esperion Th?
or
Market is currently closed. Voting is open during market hours.

Esperion Th News

Esperion Th Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Esperion Th Company Profile

Esperion Th Company Profile

Employees
479

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

Read More
  • Various studies from around the world suggest possible benefits of cholesterol drugs in the fight against COVID-19. Studies have shown that they have the potential to reduce the burden on the body from the virus by 70%. However, as a rule, thrombosis and pulmonary embolism, which are often associated with postcoid syndromes, are indicated in the side effects of such agents. I wonder if Nexletol © could be effective in treating coronavirus? This is also an anti-cholesterol drug.
    0
    • 3RD Most Shorted Stock.
      0
      • They waited for 20 million in profit, but it turned out 8 only. CEO quietly mentioned that there are 30 million (!!!) not taken into this report. 2 payments were not included in the report from Daiichi and Oberland capital (30 mln)
        0
        • I think ESPR has a lot of potential. Also a chance of a nice short squeeze.  https://www.moneyshow.com/articles/tptp2021-55871/
          0
          • ESPR is heavily shorted. seems there will be short squeeze just like #GMO and #AMC
            0
            • Buy opportunity
              0
              • great keep going up
                0
            • Buy and hold
              0
              • Good buying opportunity. Got a huge gap to close at $68.
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.